Zhangzhou Pientzehuang Pharmaceutical (600436) Q1 2025 earnings summary

Executive summary

• Net profit attributable to shareholders rose 2.59% year-over-year to RMB 999.78 million in Q1 2025.

• Operating cash flow surged 72.33% year-over-year, driven by reduced cash outflows for goods and services.

• Total assets increased 5.39% from year-end 2024, reaching RMB 18.48 billion.

Financial highlights

• Revenue was RMB 3.14 billion, down 0.92% compared to Q1 2024.

• Net profit attributable to shareholders reached RMB 999.78 million, up 2.59% year-over-year.

• Basic and diluted EPS both at RMB 1.66, up from RMB 1.62 in Q1 2024.

• Operating cash flow was RMB 915.91 million, a 72.33% increase year-over-year.

• Gross margin improved as cost of sales declined more than revenue.

Key financial ratios and metrics

• Weighted average ROE was 6.77%, down 0.26 percentage points year-over-year.

• Owner's equity attributable to shareholders rose 6.95% to RMB 15.26 billion.

• Total liabilities increased to RMB 2.64 billion, with a healthy equity ratio.